OFIX

Company Overview — What Does Orthofix Medical Inc. Do?

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas. Orthofix Medical Inc. (OFIX) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Jon C. Serbousek and employs approximately 1,090 people, headquartered in NETHERLANDS ANTILLES, Texas. With a market capitalization of $466M, OFIX is one of the notable companies in the Healthcare sector.

Orthofix Medical Inc. (OFIX) Stock Rating — Reduce (April 2026)

As of April 2026, Orthofix Medical Inc. receives a Reduce rating with a composite score of 37.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OFIX ranks #2,736 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Orthofix Medical Inc. ranks #371 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OFIX Stock Price and 52-Week Range

Orthofix Medical Inc. (OFIX) currently trades at $12.38. The stock lost $0.04 (0.3%) in the most recent trading session. The 52-week high for OFIX is $17.00, which means the stock is currently trading -27.2% from its annual peak. The 52-week low is $10.24, putting the stock 20.9% above its annual trough. Recent trading volume was 187K shares, suggesting relatively thin trading activity.

Is OFIX Overvalued or Undervalued? — Valuation Analysis

Orthofix Medical Inc. (OFIX) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.04x, versus the sector average of 2.75x. The price-to-sales ratio is 0.59x, compared to 1.66x for the average Healthcare stock.

At current multiples, Orthofix Medical Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Orthofix Medical Inc. Profitability — ROE, Margins, and Quality Score

Orthofix Medical Inc. (OFIX) earns a quality factor score of 40/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -13.8% versus the sector average of -33.1%.

On a margin basis, Orthofix Medical Inc. reports gross margins of 68.1%, compared to 71.5% for the sector. The operating margin is -12.8% (sector: -66.1%). Net profit margin stands at -14.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OFIX Debt, Balance Sheet, and Financial Health

Orthofix Medical Inc. has a debt-to-equity ratio of 89.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.45x, indicating strong short-term liquidity. Total debt on the balance sheet is $157M. Cash and equivalents stand at $63M.

OFIX has a beta of 0.89, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Orthofix Medical Inc. is 65/100, reflecting average volatility within the normal range for its sector.

Orthofix Medical Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Orthofix Medical Inc. reported revenue of $799M and earnings per share (EPS) of $-2.33. Net income for the quarter was $-117M. Gross margin was 68.1%. Operating income came in at $-101M.

In FY 2025, Orthofix Medical Inc. reported revenue of $822M and earnings per share (EPS) of $-2.33. Net income for the quarter was $-92M. Gross margin was 68.8%. Revenue grew 2.9% year-over-year compared to FY 2024. Operating income came in at $-81M.

In Q3 2025, Orthofix Medical Inc. reported revenue of $206M and earnings per share (EPS) of $-0.57. Net income for the quarter was $-23M. Gross margin was 72.2%. Revenue grew 4.6% year-over-year compared to Q3 2024. Operating income came in at $-17M.

In Q2 2025, Orthofix Medical Inc. reported revenue of $203M and earnings per share (EPS) of $-0.36. Net income for the quarter was $-14M. Gross margin was 68.7%. Revenue grew 2.3% year-over-year compared to Q2 2024. Operating income came in at $-16M.

Over the past 8 quarters, Orthofix Medical Inc. has demonstrated a growth trajectory, with revenue expanding from $199M to $799M. Investors analyzing OFIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OFIX Dividend Yield and Income Analysis

Orthofix Medical Inc. (OFIX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OFIX Momentum and Technical Analysis Profile

Orthofix Medical Inc. (OFIX) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

OFIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Orthofix Medical Inc. (OFIX) ranks #371 out of 838 stocks based on the Blank Capital composite score. This places OFIX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OFIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OFIX vs S&P 500 (SPY) comparison to assess how Orthofix Medical Inc. stacks up against the broader market across all factor dimensions.

OFIX Next Earnings Date

No upcoming earnings date has been announced for Orthofix Medical Inc. (OFIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OFIX? — Investment Thesis Summary

The quantitative profile for Orthofix Medical Inc. suggests caution. The value score of 25/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. Low volatility (stability score 65/100) reduces downside risk.

In summary, Orthofix Medical Inc. (OFIX) earns a Reduce rating with a composite score of 37.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OFIX stock.

Related Resources for OFIX Investors

Explore more research and tools: OFIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OFIX head-to-head with peers: OFIX vs AZN, OFIX vs SLGL, OFIX vs VMD.